Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: The company earned $728 million, or 67 cents per share, in the fourth quarter. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring. “Company sales were stronger than thought, but a lot of that upside came from drugs that are already off patent or about to lose patent protection,” said Edward Jones analyst Judson Clark. Excluding special items, Lilly earned 74 cents per share, matching analysts’ average forecasts, according to Thomson Reuters I/B/E/S. Shares in the company dropped 1.4 percent to 53.21, after earlier reaching their lowest in two weeks at $53.05. Lilly’s global sales fell 2 percent to $5.81 billion, but topped Wall Street forecasts of $5.46 billion. Sales would have been flat if not for the stronger dollar, which lowers the value of sales in overseas markets. Sales of Cymbalta, which lost U.S. patent protection last month, fell 38 percent to $883 million. But they came in about $100 million higher than Wall Street expected, analysts said. Lilly’s sales, earnings, and its share price, have been badly hurt since late 2011, when its Zyprexa schizophrenia drug lost U.S. patent protection. Once Lilly’s biggest product, with annual sales of $5 billion, it now has sales of only $1.5 billion. The situation worsened last month, when Cymbalta - which also had $5 billion in annual sales at its peak - began facing cheaper generics in the United States. The company’s “patent cliff” will become more daunting in March, when $1 billion-a-year osteoporosis drug Evista faces U.S. generics. “We haven’t wasted the crisis,” Chief Executive John Lechleiter said Thursday in a conference call with industry analysts. “We’re more agile, we’re leaner and I believe we’re better operators today.”  Lilly has cut more than 5,000 employees from its workforce in order to reduce annual costs by $1 billion over the last three years to deal with patent expirations on its drugs. It has also restructured itself to focus on cancer and diabetes - lucrative specialties that are two of the company’s longstanding strengths. Clark said sales of Cymbalta could eventually decline 80 percent, which has been the case for many other blockbuster medicines in recent years. He questioned whether gains for other products seen in the fourth quarter will be sustainable. Sales of many products over the quarter showed double-digit sales increases, including Lilly’s Humalog insulin, Cialis anti-impotence treatment, Forteo and Evista osteoporosis drugs, and Straterra for attention deficit disorder. But price increases in the United States accounted for much of those sales gains. The Indianapolis drugmaker is expecting a return to company sales growth next year, from increased sales of drugs that still have patent protection and from launches of new treatments for cancer and diabetes. It hopes to launch three new drugs this year: ramucirumab for stomach cancer, and dulaglutide and empagliflozin for type 2 diabetes - the most common form of the disease, which is closely linked to obesity. Although analysts have forecast annual sales of more than $650 million for ramucirumab, they are concerned the new diabetes drugs may have a hard time competing with similar drugs already on the market. The company has introduced no new products in recent years. In a recent interview, Lechleiter said it was time for Lilly “to go back on offense”, helped by a pipeline of nearly 40 medicines in mid- and late-stage studies, compared with only seven in those stages of development a decade ago. Claim: Lilly's quarterly sales largely offset Cymbalta slide.
Drugmaker Eli Lilly and Co’s quarterly revenue fell far less than expected, it reported on Thursday, as plunging sales of its Cymbalta depression treatment were largely offset by higher revenues for most of its other prescription drugs.

Paragraph: In December 2016, a video went viral, purportedly showing a man punching a kangaroo in order to save a dog:  Matthew Amor, who organized the trip in support of a friend who was battling an incurable disease, detailed the events that led to his friend punching a kangaroo to News.com.au: Mr Amor said it was totally out of character for his friend, Mr Tonkins, to hit the marsupial, describing him as a “placid bloke”. “My mate has a good government job, so he’s gone pretty quiet on this,” Mr Amor laughed. “We were driving along, the dogs are loose. They are trained to smell pig’s blood, and picked up a scent. “The dogs went past 20 kangaroos, which they are trained not to touch. “Anyway, this big buck got a hold of my friend’s dog. It just grabbed him.” Shortly after the video went viral, many people called on Taronga’s Western Plains zoo to fire Tonkins for punching the kangaroo. However, the zoo released a statement on 6 December 2016, saying that the incident did not put Tonkins’ position in jeopardy: Best practice animal welfare and the protection of Australian wildlife are of the utmost importance to Taronga. Taronga strongly opposes the striking of animals and does not support the practice of using dogs to hunt, as this can result in negative welfare for both species. We support the Guidelines outlined by the Department of Environment and Heritage in the event of confrontation with a kangaroo. Mr Tonkins is an experienced Zoo keeper and during his six years at Taronga Western Plains Zoo has always followed Taronga’s best practice approach to animal care and welfare. We confirm that there is no suggestion of Mr Tonkins’ employment at Taronga Western Plains Zoo ending as a result of this event. However, the highest standards of animal welfare and care are a core value of Taronga and one that we expect our staff to uphold in all their interactions with wildlife and we continue to work with Mr Tonkins on his conduct in regards to this incident. Kangaroos are often portrayed as cuddly and gentle marsupials and are generally docile, but can be quite vicious and even dangerous (kicking with their muscular back legs, using feet topped by razor-sharp nails as weapons) when they feel threatened (often by dogs). Claim: A viral video shows a man punching a kangaroo in the face to save his dog.
In this case, though, all parties — dog, man, and kangaroo — emerged from the confrontation relatively unscathed.

Paragraph: Tyson Foods said in a Tuesday news release that 212 workers at its plant in Madison tested positive for the virus; 74 of them had no symptoms. The numbers were the results from testing from May 1-4 of 1,467 workers, contractors and vendors at the plant, and the results were released jointly by Tyson and the Elkhorn Logan Valley Public Health Department . The plant was shut down in early May for deep cleaning and sanitization in the wake of a surge in coronavirus cases among meatpacking plant workers. Tyson workers who test positive receive paid leave and may return to work only when they have been medically cleared to do so, the company said. Tyson said most of those workers who tested positive are considered to be already recovered. Returning workers will undergo daily health screenings and temperature checks before they are allowed to enter the plant, the company said, and all workers will be provided mandatory face masks. A range of social distancing measures — including physical barriers between workstations and in break rooms — will also be practiced. Madison is about 100 miles (161 kilometers) northwest of Omaha. Claim: 212 at Nebraska meat plant test positive for COVID-19.

More than 200 workers at a northeastern Nebraska pork processing plant have tested positive for COVID-19, according to plant owners and local health officials.